published meta-analysis   sensitivity analysis   studies

tofacitinib in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsSTOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] 0.49[0.15; 1.62]STOP-COVID (Guimarães), 202110%289NAnot evaluable deathsdetailed resultsSTOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] 0.49[0.15; 1.62]STOP-COVID (Guimarães), 202110%289NAnot evaluable clinical deteriorationdetailed resultsSTOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07] 0.54[0.27; 1.07]STOP-COVID (Guimarães), 202110%NAnot evaluable death or ventilationdetailed resultsSTOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97] 0.63[0.41; 0.97]STOP-COVID (Guimarães), 202110%289NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-29 13:37 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1045 - roots T: 290